Pinned Tweet
$NVCT Multiple Near-Term Catalysts Could Drive a Major Re-Rating
Streamlined U.S. FDA Approval for NXP100 and Upcoming Clinical Data Could Establish NXP200 as a Leading Next-Generation BRAF Inhibitor
See our free report at trufflepigs.substack.com
Key Investment Highlights
•NXP100 — Major FDA catalyst: A streamlined U.S. regulatory pathway could eliminate the need to repeat Haisco’s two successful Phase 3 PNH studies, accelerate NDA submission by one to two years, and add $400–$800M ($12–$24/share) in estimated asset value.
•NXP200 — Major oncology data catalyst: Glioma data demonstrate a 40.7% response rate, four complete responses, exceptionally deep tumor reductions, and durable activity in patients previously treated with BRAF inhibitors. The improved salt formulation has also shown preliminary extracranial activity. Upcoming data could add $1B or more ($30+/share) in estimated asset value.
•Institutional accumulation and constrained liquidity: Soleus Capital, Tang Capital, and Braidwell each hold more than 1.5M shares. Approximately 2.54M shares short against our proprietary estimate of a 7.3M-share effective trading float could amplify a catalyst-driven re-rating.
•Substantial valuation discount and upside: $NVCT trades near $20, with a market cap of $700M, versus our $2.5B current risk-adjusted asset valuation (~$73/share). This comprises $2B for NXP100 under conventional U.S. Phase 3 development assumptions and $500M for NXP200 based solely on existing glioma results. Favorable FDA and oncology outcomes could increase combined asset values to $3–5B (~$87–$145/share), substantially above our base case.
The deal was announced on June 22, just a week before the Russell 2000 rebalance. $NVCT had rocketed from $10 to over $20 in the two weeks leading up to the announcement. That enormous increase in market cap effectively doubled its weighting in the new Russell index, forcing index buyers to scramble for shares in the final week before the rebalance, just as buyers in the deal were also scooping up shares.
Much of that gain was therefore artificial, driven by index-related demand rather than a fundamental revaluation. Biotech funds weren’t going to pay for that temporary spike, which is why the deal appeared to be priced at a much larger discount than was actually the case.
Look at the top-tier funds that participated: Perceptive, Soleus, Tang, Sphera, Iridian, among others. Since then, another fund reportedly acquired a >5% stake at $23, and Soleus increased its position by 60% post-deal. The new fund should be revealed in filings next week.
I’ve heard from well-connected industry friends that buyers in the deal valued NXP100 alone at roughly $2 billion at the time, without even bothering to evaluate the oncology portfolio. At the deal price, NVCT was trading at approximately a 65% discount to what they considered the intrinsic value of only NXP100.
And here’s what makes this particularly interesting: that $2 billion valuation didn’t incorporate the possibility of a more streamlined FDA pathway for NXP100 or assign any value whatsoever to NXP200 or NXP900. A favorable regulatory pathway for NXP100, combined with positive NXP200 data, could therefore drive a massive revaluation of the stock.
So why has the stock languished? These large biotech funds can’t easily accumulate meaningful positions in such an illiquid stock through open-market purchases. They’re largely stealth buyers, while retail investors don’t seem to appreciate the underlying value or the significance of the institutional ownership.
That’s really why I’m posting about NVCT. I believe the disconnect between the current stock price and intrinsic value represents a rare opportunity for truly outsized gains.
Replying to @JD4for4
Fair on the funding. The $100 million covered the $20 million Haisco upfront and the development bill. The raise priced 5 million shares at $20. The stock was $28.50 the week before. That's a 30 percent discount. Four months later the stock still trades around $20. Deal buyers are flat. Holders from June are down about 30 percent. If NXP100 reaches your $5 billion, the raise is 2 percent of that and dilution stops mattering. Until then the market prices the return as unproven, and the stock sitting at the raise price is the evidence.
1
5
1,058
Jordan Alexander retweeted
💯!
The biggest threat to our U.S. competitiveness vs. China are the self-inflicted toxic policies by U.S. government: IRA, pill penalty, MFN, 340B, FDA chaos, NIH cuts and political review, anti-immigration policies, anti-science/anti-vaxx stances, etc.
Let’s beat China with American ingenuity and a pro-innovation policy environment, not walls, barriers, and COINs with consequences that harm patient access to medicines!
Talk of China competing with US biotech has sparked interest in protectionism (coins), which, like mistaking a boomerang for a stick, rarely works out the way you think.
It’s cool to see many here speak passionately about preserving US biopharma like it’s the most important thing ever.
But the greatest threat to US biopharma is our own government and America’s misunderstanding and hatred of pharma, not China. It’s the calls for price controls and patent waivers from Congress. The pill penalty (also impacts oligos) causes harm. MFN causes harm (now companies give up on factoring ex-US sales into their plans, reducing value of success and incentives for trying).
That we have as much R&D still going on is testament to how much of the pro-innovation policy framework remains intact (for now, pill penalty only applies to non-orphan diseases of aging) and how modestly revenues from other countries contributed to investment calculus before. But that shouldn’t make anyone think US biopharma is safe from flawed policy. More price controls and continued MFN will deter investment, coins or no coins.
So I hope Americans are proud and protective of their biopharma sector (most aren’t actually unless it’s versus China). If you are curious about what set of policies would bolster biotech and pharma and solve the affordability challenges Americans are demanding Congress solve, follow the work of No Patient Left Behind, the advocacy organization my peers and I started to actually fix what needs fixing. Details in next comments.
@NPLB_org
Jordan Alexander retweeted
Talk of China competing with US biotech has sparked interest in protectionism (coins), which, like mistaking a boomerang for a stick, rarely works out the way you think.
It’s cool to see many here speak passionately about preserving US biopharma like it’s the most important thing ever.
But the greatest threat to US biopharma is our own government and America’s misunderstanding and hatred of pharma, not China. It’s the calls for price controls and patent waivers from Congress. The pill penalty (also impacts oligos) causes harm. MFN causes harm (now companies give up on factoring ex-US sales into their plans, reducing value of success and incentives for trying).
That we have as much R&D still going on is testament to how much of the pro-innovation policy framework remains intact (for now, pill penalty only applies to non-orphan diseases of aging) and how modestly revenues from other countries contributed to investment calculus before. But that shouldn’t make anyone think US biopharma is safe from flawed policy. More price controls and continued MFN will deter investment, coins or no coins.
So I hope Americans are proud and protective of their biopharma sector (most aren’t actually unless it’s versus China). If you are curious about what set of policies would bolster biotech and pharma and solve the affordability challenges Americans are demanding Congress solve, follow the work of No Patient Left Behind, the advocacy organization my peers and I started to actually fix what needs fixing. Details in next comments.
@NPLB_org
$NVCT 3Q update was unusually revealing, w/ two big positive developments —
For NXP100, a streamlined FDA pathway could make US approval practically a foregone conclusion, given its two successful P3s, comparable results from two P3s of $NVS Fabhalta, a chemical analog & FDA’s recognition that factor B inhibition works similarly across ethnic groups.
For NXP200, upcoming data in patients who failed BRAF inhibitors could reveal something far more valuable than a best-in-class drug: a breakthrough in overcoming acquired BRAF resistance.
Clarity on NXP100’s FDA pathway & strong upcoming NXP200 data could drive a major revaluation of both assets. I think it’s entirely possible NVCT’s market cap could 2x to > $1B, taking the stock from ~$20 to $40.
My biggest takeaways:
NXP100: Based upon very favorable interactions w/ FDA, management pointed to two likely FDA pathways, ranging from a small uncontrolled study to the former base case of a repeat of the Haisco studies in a US trial. My base case has been two controlled trials but I think NVCT may be pointing to a more streamlined approach, possibly a single uncontrolled study.
The Chinese P3s already provide compelling scientific evidence for approval. NVCT sounded confident FDA questions about comparability w/ US standards & Fabhalta’s trials have been addressed. Fabhalta’s P3s included 40% Asian patients & FDA previously recognized similar efficacy across ethnic groups.
One possibility is a single uncontrolled study of ~35–40 Western patients demonstrating maintenance of Hb comparable to the Chinese data. Two studies remain possible but the final pathway could be far less burdensome than expected.
NXP100 already has two successful P3s & Chinese approval for PNH w/ efficacy comparable to Fabhalta P3s. Regardless of the path required, I think eventual approval becomes about as close to a foregone conclusion as you get in biotech.
Between PNH, IgAN & other complement-mediated diseases, I see a potential $5B annual revenue opportunity & believe NXP100 alone could ultimately be worth $5B.
NXP200 could be even more interesting.
The glioma data are remarkable: 40% ORR in HGG, incl 3 CRs, with 87.5% of responders achieving >80% tumor reduction. 2/3 patients previously treated w/ BRAF inhibitors had deep, durable ongoing responses lasting >14 & 17 months.
And that was before Haisco developed the improved salt formulation, which substantially improved PK. A small pilot subsequently showed encouraging activity outside CNS, incl 2 PRs (-59% & 50% tumor reductions) & 2 SD (-27% & -12%) among 5 CRC patients. Importantly, the -27% SD was a BRAF resistant patient & response was ongoing > 6 months.
But the biggest revelation was management’s discussion of the next Chinese P1b update coming in next 2-3 months, potentially including 15–17 patients who previously failed BRAF inhibitors.
Management suggested even a 20–25% response rate would be a major success. Stronger results could move NXP200 beyond a best-in-class paradox breaker into the rare category of truly important oncology drugs. Overcoming acquired BRAF resistance is the “holy grail.”
I found management’s public confidence striking. These are open-label Chinese studies, and Haisco shares clinical information with NVCT. We don’t know what they’ve seen, but I find it hard to believe management would publicly set such an ambitious benchmark without some basis for confidence.
Haisco’s actions reinforce that view. Only 5 months after initiating the broader P1b, it launched a separate 182-patient CRC study. That’s a substantial investment suggesting real conviction in the drug.
Another important disclosure concerned the US glioma strategy. Management discussed adding ~25–35 US patients to the existing 27-patient Chinese dataset, potentially supporting Breakthrough Therapy Designation and an accelerated regulatory pathway. If efficacy and durability are confirmed, I think the US P1b could potentially serve as a pivotal study.
See our $NVCT truffle pigs substack report at trufflepigs.substack.com
trufflepigs.substack.com/p/n…
Please subscribe for free and share our posts to support our work.
2
454
Laidlaw reiterates Buy and $35 PT on $NVCT following impressive NXP200 ESMO data, highlighting deep tumor responses, activity in previously BRAF-treated patients, and a differentiated clinical profile.
6
1,138
$NVCT Truffle Pigs Substack: Nuvectis Pharma’s NXP200: ESMO Results Strengthen the Case for a Differentiated BRAF Inhibitor
Haisco’s latest ESMO presentation provided compelling new data for Nuvectis Pharma’s NXP200, an oral, brain-penetrant BRAF paradox breaker.
The standout findings were exceptional tumor shrinkage and encouraging activity after prior BRAF treatment. Two previously treated patients achieved >80% tumor reduction.
The data shows a 40% response rate in recurrent or progressive high-grade glioma, including 3 complete responses among 20 patients (one preliminary).
A few highlights:
• 87.5% of high-grade glioma responders experienced >80% tumor reduction.
• Two of three patients previously treated with BRAF inhibitors achieved >80% tumor shrinkage and remained on therapy beyond 14 and 17 months.
• Median overall survival reached 17.2 months, with a 94.4% one-year survival rate in high-grade glioma.
• Only 14.3% experienced grade ≥3 treatment-related adverse events, with no treatment discontinuations due to adverse events.
These results were generated using the original formulation of NXP200. Haisco has since developed a sodium-salt formulation with substantially improved systemic drug exposure.
In an early 7-patient pilot study, the new formulation produced 3 confirmed partial responses, including 2 of 5 colorectal cancer patients with tumor reductions of 59% and 50.2%. Another colorectal patient with prior BRAF resistance experienced 27% tumor shrinkage.
The colorectal results are particularly noteworthy because BRAF inhibitor monotherapy has historically shown limited efficacy in this disease, while competing paradox breakers have yet to establish broad activity across non-CNS tumors.
Haisco has made a substantial commitment to further development, launching a 159-patient basket study across BRAF-mutated solid tumors in March and a separate 180-patient colorectal cancer study in August.
The new salt formulation has also received Breakthrough Therapy Designation in China for recurrent or progressive high-grade glioma.
The potentially larger commercial opportunity lies in patients whose cancers have progressed on existing BRAF inhibitors. If NXP200 can demonstrate meaningful activity in resistant disease while expanding into common non-CNS cancers, its addressable market could be considerably larger than glioma alone.
While NXP100 has attracted significant institutional interest in $NVCT, NXP200 has largely been treated as a free call option in the company’s valuation. The emerging clinical evidence should support a meaningful reassessment of NXP200’s value and upside in the shares, with a potential multibillion-dollar opportunity if activity in BRAF-resistant cancers is confirmed and the improved salt formulation delivers broader efficacy.
Our latest Truffle Pigs Research report examines the ESMO results, the evidence of activity following prior BRAF treatment, and the broader commercial opportunity.
trufflepigs.substack.com/p/n……
#ESMO2026
Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas
Read the full release app.irinbox.com/pr/NVCT/nvct… $NVCT
Jordan Alexander retweeted
I believe there's a high % chance $QURE gets its approval. Stuff like this from the FDA, in my eyes, further strengthens that belief.
They want to generally make the review criteria more clear, more patient (advocacy) focused, and more flexible about what evidence is reasonably attainable. Not lenient for the sake of being reckless, but because there are situations that warrant different criteria.
I think it would be quite incongruent to be vocally advocating for these new policies (which are suspiciously similar to the QURE debacle), while simultaneously crushing a high-profile drug approval like AMT-130. Incongruent doesn't mean it can't happen, just that it seems like the tail outcome.
"The new framework is intended to enable patient input at earlier stages and at milestones throughout the development and review process. It also aims to provide greater clarity and consistency to drug developers on regulatory decision making. The agency said in a statement that it should take into account what evidence is reasonably attainable, given the nature of rare diseases."
To be clear, FDA officials denied that the initiative was motivated by the earlier controversies. The connection to AMT-130, and the positive read-through, is my interpretation.
"In an interview, senior officials at the agency denied that the initiative had anything to do with the earlier controversies"
---
Disclosure: Creek Drive and its affiliated funds holds positions in QURE. Views expressed are current opinions for information only, subject to change and are not investment advice or a recommendation to buy or sell any security. Investing involves the risk of loss and past performance is not indicative of future performance. See the disclosures link in my bio for more important information.
FDA is transforming rare disease drug approvals. The new Rare Disease Framework Initiative will work to give patients more voice, give developers more clarity, and eliminate surprises in the regulatory process. bloomberg.com/news/articles/…
Jordan Alexander retweeted
Replying to @aintnothing1234 @uniQure_NV
$qure $clpt
Data is data, definitely much different than the headlines or perception of these 4 year results. People should be shouting from the rooftops on what they just truly produced. It really isn’t very complicated and therefore I would have to hope the FDA could clearly see what has happened. I can’t say I am super concerned that the FDA will not see the same thing.
I know this might sound like an insane take, Uniqure has come much closer to truly halting the disease of Huntington’s than anyone can truly imagine. This is why Victor Sung says, well, my 6 patients that are now over 5 years are still stable. Same with the rush patient. These are factual statements.
Why? Because they are stable, we just saw that, TFC got better in year 4.
Does the FDA agree or disagree that TFC is the most important thing to track in HD? The literature and recent conversations with the FDA agree with that statement.
Jordan Alexander retweeted
$qure $clpt
Serious question here, how do we explain the exact starting point track hd tfc 12.2, amt 130 was 12.2 on the high dose starting.
2024 decision modeling analysis using TRACK HD data estimated a 36 month TFC change of −1.989 for the TFC 11–13.
AMT-130 high dose: −0.27 tfc at 36 months, n=15
We can agree this isn't 100% like for like, but the starting TFC is remarkably similar, and the populations are in a comparable early functional range
You have that plus the 2000 study of 575 patients with baseline showing per year 0.97 points loss for tfc 7-13. Check out all the studies below.
Historically, patients with higher baseline TFC have generally shown faster TFC decline than patients with lower baseline TFC.
Uniqure had a loss of 0.37 points at 4 years.
The updated Enroll-HD external control shows −0.94 TFC points at 48 months, while the earlier Enroll-HD control produced approximately −1.24 points. Again, I ask here, are these aggressive or conservative control numbers? Where are all the 2 year, 3 year, 4 year studies in hd showing anything like these numbers?
2024 track hd study
pmc.ncbi.nlm.nih.gov/article…
2000 study
Tfc 7-13
0.97 per year
neurology.org/doi/10.1212/WN…
The CREST-E study of creatine for Huntington disease: A randomized controlled trial
N 278
Starting baseline 10.18
Estimated placebo TFC decline was 0.70 points/year; the trial was designed for up to 48 months but was stopped early, with only 36 participants having ≥4 years of primary outcome data.
pubmed.ncbi.nlm.nih.gov/2870…
dash.harvard.edu/server/api/…
2CARE study
609 participants
Starting baseline 10.9
0.83/year
only 34% of participants had completed 5 years of follow-up at the time of study termination, although 91% had completed at least 1 year of follow-up and 69% had completed 3 years
pmc.ncbi.nlm.nih.gov/article…
@peter_mantas @Tim_Corr @laurencurehd @Christina4HD @JRenz0418 @DesertDweller93
Jordan Alexander retweeted
H.C. Wainwright keeps a Buy rating and $185 PT on $NKTR after the Co. presented AA data at #EADV2026 and hosted a conference call to review the data.
$QTTB $NBI
H.C. Wainwright said in its note: Of the eight patients who achieved SALT ≤20 after 52 weeks of rezpeg treatment, 75% (6/8) maintained the response at four months and 63% (5/8) at six months off treatment (NRI, with all patients available for assessment), versus an estimated 30% and 20% for low-dose baricitinib (2 mg) after the same 52 weeks of treatment (cross-trial comparison, Exhibit 1).
Response was also independent of current episode duration, a key prognostic factor in AA: among patients who entered the 16-week treatment extension, 29% with a current episode of <4 years and 30% with an episode of 24 years achieved SALT ≤20 at Week 52, whereas baricitinib 2 mg response fell from an estimated 28% to 11% across the same cut (Exhibit 2).
Most notably, responses kept deepening without drug.
During the six-month off-treatment period, 41% of the 27 patients in the 52-week treatment cohort achieved a deeper best response than on treatment and another 22% maintained their regrowth (Exhibit 3), while SALT ≤10 rose from 7% at Week 52 to 19% (Exhibit 4) and one patient reached SALT 0.
Despite these results, NKTR shares fell 22.4% to $46.99 on October 1, versus a 2.1% decline in the Nasdaq Biotechnology Index (NBI).
We view the move as unjustified and believe the stock is oversold.
We maintain our Buy rating on NKTR and a 12-month price target of $185 per share.
Canaccord Genuity🏁 $NKTR Buy-$153 and said in its initiation report that the Ph3 program for lead asset rezpegaldesleukin in atopic dermatitis has commenced and a Ph3 program in alopecia areata is expected following an end-of-Phase 2 meeting with the FDA—expects rezpeg's unique mechanism of action to appeal to patients and physicians alike, if approved.
Rezpeg has two big advantages in the dermatology space, namely its potential for disease modification and safety.
For anyone freaking out over $NKTR ISRs, this wasn’t new & was the same data previously disclosed. Nearly all reactions were mild to moderate, typically resolved within days & none led to discontinuation. It’s a tolerability issue, but one that was generally well tolerated & potential for < frequent dosing could help further. Very different from the systemic safety concerns & boxed warnings associated with AA JAK inhibitors.














